Low frequency of MAP kinase pathway alterations in KIT and PDGFRA wild-type GISTs
- PMID: 19614767
- DOI: 10.1111/j.1365-2559.2009.03323.x
Low frequency of MAP kinase pathway alterations in KIT and PDGFRA wild-type GISTs
Abstract
Aims: Gastrointestinal stromal tumours (GISTs) are commonly driven by oncogenic mutations in KIT and PDGFRA. However, 10-40% of these patients are wild-type for these genes. The prognostic significance of wild-type GISTs is controversial, and they rarely respond to imatinib. The aim of this study was to elucidate the molecular lesions underlying wild-type GISTs tumorigenesis.
Methods and results: Twenty-nine KIT and PDGFRA wild-type GISTs were re-assessed for the presence of 'cryptic'KIT exon 11 duplications. Using a specific polymerase chain reaction assay, three previously undetected mutations were identified. In the remaining 26 wild-type GISTs, KIT, stem cell factor (SCF), phospho-KIT and phospho-ERK expression was evaluated by immunohistochemistry. Samples were screened for gain-of-function mutations in the mitogen-activated protein kinase (MAPK) cascade. KIT and SCF co-expression associated with KIT activation was observed in approximately 30% of cases. Furthermore, phospho-ERK expression showed that MAPK is activated in approximately 30% of cases. None of RAS family (H-, K- and N-RAS) oncogenes exhibited activating mutations, whereas BRAF mutations were found in approximately 4% of cases.
Conclusions: In the absence of RAS mutations, MAPK could be activated through SCF/KIT autocrine/paracrine mechanisms and/or mutated BRAF in a subset of KIT/PDGFRA wild-type GISTs.
Similar articles
-
V600E BRAF mutations are alternative early molecular events in a subset of KIT/PDGFRA wild-type gastrointestinal stromal tumours.J Clin Pathol. 2009 Jul;62(7):613-6. doi: 10.1136/jcp.2009.064550. J Clin Pathol. 2009. PMID: 19561230
-
The activated targets of mTOR signaling pathway are characteristic for PDGFRA mutant and wild-type rather than KIT mutant GISTs.Diagn Mol Pathol. 2011 Mar;20(1):22-33. doi: 10.1097/PDM.0b013e3181eb931b. Diagn Mol Pathol. 2011. PMID: 21326036
-
Spectrum of KIT/PDGFRA/BRAF mutations and Phosphatidylinositol-3-Kinase pathway gene alterations in gastrointestinal stromal tumors (GIST).Cancer Lett. 2011 Dec 15;312(1):43-54. doi: 10.1016/j.canlet.2011.07.029. Epub 2011 Aug 6. Cancer Lett. 2011. PMID: 21906875
-
Clinical significance of oncogenic KIT and PDGFRA mutations in gastrointestinal stromal tumours.Histopathology. 2008 Sep;53(3):245-66. doi: 10.1111/j.1365-2559.2008.02977.x. Epub 2008 Feb 28. Histopathology. 2008. PMID: 18312355 Review.
-
Clinicopathological and molecular features of a large cohort of gastrointestinal stromal tumors (GISTs) and review of the literature: BRAF mutations in KIT/PDGFRA wild-type GISTs are rare events.Hum Pathol. 2017 Apr;62:206-214. doi: 10.1016/j.humpath.2017.01.005. Epub 2017 Feb 1. Hum Pathol. 2017. PMID: 28159677 Review.
Cited by
-
Overview of MDM2 and B-RAF Expression in Gastric Lesions.Open Access Maced J Med Sci. 2018 Oct 10;6(10):1795-1802. doi: 10.3889/oamjms.2018.338. eCollection 2018 Oct 25. Open Access Maced J Med Sci. 2018. PMID: 30455751 Free PMC article.
-
Lack of microsatellite instability in gastrointestinal stromal tumors.Oncol Lett. 2017 Nov;14(5):5221-5228. doi: 10.3892/ol.2017.6884. Epub 2017 Sep 4. Oncol Lett. 2017. PMID: 29113157 Free PMC article.
-
ACRIN 6665/RTOG 0132 phase II trial of neoadjuvant imatinib mesylate for operable malignant gastrointestinal stromal tumor: monitoring with 18F-FDG PET and correlation with genotype and GLUT4 expression.J Nucl Med. 2012 Apr;53(4):567-74. doi: 10.2967/jnumed.111.094425. Epub 2012 Mar 1. J Nucl Med. 2012. PMID: 22381410 Free PMC article. Clinical Trial.
-
Cytotoxicity of allitinib, an irreversible anti-EGFR agent, in a large panel of human cancer-derived cell lines: KRAS mutation status as a predictive biomarker.Cell Oncol (Dordr). 2016 Jun;39(3):253-63. doi: 10.1007/s13402-016-0270-z. Epub 2016 Feb 26. Cell Oncol (Dordr). 2016. PMID: 26920031
-
The metabolic microenvironment of melanomas: Prognostic value of MCT1 and MCT4.Cell Cycle. 2016 Jun 2;15(11):1462-70. doi: 10.1080/15384101.2016.1175258. Epub 2016 Apr 22. Cell Cycle. 2016. PMID: 27105345 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Research Materials
Miscellaneous